Netherlands· NL-5493c7827649
Zoladex-3,6, implantatiestaafje 3,6 mg
A goserelin product containing goserelineacetaat, registered in Netherlands by AstraZeneca B.V. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Goserelin is registered in 12 of 19 countries.
Countries holding a registration under ATC L02AE03 (goserelin), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Goserelin · ATC L02AE03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of goserelin costs, country by country.
Normalised to the WHO defined daily dose (0.129 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Goserelin · price per daily dose (0.129 mg)
USD · FX 28 Sept 2026
- CH Switzerland$5.39
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GOSERELINEACETAAT
- Manufacturer
- AstraZeneca B.V
- Country
- Netherlands (NL)
- ATC code
- L02AE03
- ATC class
- Goserelin
- Defined daily dose
- 0.129 mg, Implantat
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id12277
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
461 interactions on record for goserelin.
Graded by severity as the source publishes them — 71 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Goserelin · interactions on record
461 records
- 71 severe
- 250 moderate
- 3 minor
- 137 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Goserelin in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZoladex 3,6 mgAktuapharma
- PolandReseligoZentiva, k.s.
- SwitzerlandZoladex SafeSystem, Fertigspritze mit ImplantatAstraZeneca AG
- NorwayZoladexAstraZeneca
- FinlandZoladexParanova Oy
- SwedenZoladex 10,8 mg Implantat i förfylld sprutaOrifarm AB
- United KingdomGoserelin 3.6mg implant pre-filled syringesA A H Pharmaceuticals Ltd
- GermanyGoserelin EndomedicaEndomedica Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Zoladex Depot
- Belgium · Zoladex, Zoladex Long Acting
- Bulgaria · Золадекс, Золадекс Lа
- Cyprus · Zoladex
- Czechia · Reseligo, Zoladex Depot
- Germany · Goserelin Endomedica, Gosgon
- Denmark · Zoladex
- Estonia · Reseligo, Zoladex
- Spain · Zoladex, Zoladex Trimestral
- Finland · Zoladex
- France · Zoladex
- United Kingdom (Northern Ireland) · Zoladex, Zoladex La
- Greece · Implandex, Implandex La
- Croatia · Reseligo, Zoladex
- Hungary · Reseligo, Zildalis
- Ireland · Zoladex, Zoladex La
- Iceland · Reseligo, Zoladex
- Italy · Zoladex
- Lithuania · Algonad, Reseligo
- Luxembourg · Zoladex, Zoladex Long Acting
- Latvia · Reseligo
- Malta · Golexin, Golexin La
- Norway · Zoladex
- Poland · Reseligo, Xanderla
- Portugal · Golexin, Golexin La
- Romania · Reseligo, Zoladex
- Sweden · Zoladex
- Slovenia · Reseligo, Zoladex
- Slovakia · Reseligo, Zoladex Depot
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c2122b21-a577-4666-8bf6-01f94bb708eb GET /v1/drugs/c2122b21-a577-4666-8bf6-01f94bb708eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Implantatietablet",
"route": null,
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h12277_smpc.pdf",
"strength": null,
"atc_label": "Goserelin",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg12277",
"excipients": [
"MELKZUUR(D,L)-GLYCOLZUUR COPOLYMEER"
],
"substances": [
"GOSERELINEACETAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h12277.pdf",
"authorised_at": "1988/10/03",
"procedure_number": null,
"dispensing_status": "Uitsluitend recept",
"registration_number": "12277",
"additional_monitoring": "N"
}See everything about goserelin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.